Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson’s disease and acetylcholinesterase inhibitors in Parkinson’s disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data

Abstract

Background The concurrent use of anticholinergics and acetylcholinesterase inhibitors (ACHEIs) in Parkinson’s disease (PD) patients with dementia should be avoided because the opposing pharmacological actions of both drugs reduce the treatment efficacy. We aimed to investigate the prevalence of the concurrent use of these two types of drugs in Korean patients. Methods In the 2017 Health Insurance Review and Assessment Service–National Aged Patient Sample data, comprising insurance claims records for a 10% random sample of patients aged ≥ 65 years in Korea, “concurrent use” was defined as the overlapping of anticholinergic and ACHEI doses for at least 2 months. Results Among 8,845 PD patients with dementia, 847 (9.58%) were co-administered anticholinergics, used to treat the motor symptoms of PD, and ACHEIs for a mean duration of 7.7 months. A total of 286 (33.77% of all co-administered) patients used both drug types concurrently all year. About 80% of concurrent users were prescribed each drug by the same prescriber, indicating that coadministration may not be due to a lack of information sharing between providers. Logistic regression analysis showed that patients mainly treated at clinics (odds ratio (OR), 1.541; 95% confidence interval (CI), 1.158–2.059), hospitals (OR, 2.135; 95% CI, 1.586–2.883), and general hospitals (OR, 1.568; 95% CI, 1.221–2.028) were more likely to be co-prescribed anticholinergics and ACHEIs than those mainly treated at tertiary-care hospitals. PD patients with dementia treated at healthcare organizations located in areas other than the capital city had an approximately 22% higher risk of concurrent use (OR: 1.227, 95% CI: 1.046–1.441). Conclusions The concurrent use of anticholinergics for the motor symptoms of PD and ACHEIs in elderly Korean PD patients with dementia cannot be ignored, and strategies that mitigate potentially inappropriate concurrent drug use are required.

Vanillin derivatives as antiamnesic agents in scopolamine-induced memory impairment in mice

“…AChE inhibition is also considered as a remedial strategy for other types of neuronal disorders like dementia and Parkinson's diseases. Many Schiff bases synthesized in various parts of the world have been evaluated for anti-amnesic and anti-Alzheimer's activity with excellent activities [ 51 ].…”

The Impact of Pesticides on Parkinson's Disease; A Case-Control Study

“…Meanwhile, exposure to OPPs inhibits AChE activity via phosphorylation of the hydroxyl group of serine at the active site (7). Recent studies have shown that AChE activity and, therefore, acetylcholine levels change in patients with PD (8,9). These pesticides can also inhibit paraoxonase-1 (PON1) activity (10).…”